Compare Monster Beverage Corp (MNST) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Moderna, Inc. — how do they compare? Monster Beverage Corp trades at $43.64 (market cap $85.51B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Monster Beverage Corp and Moderna, Inc. are close in size by market cap, and Moderna, Inc. is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Moderna, Inc. for 59 Days on average.
| MNST | MRNA | |
|---|---|---|
Market Cap | $85.51B | $78.65B |
Volume | 8,569,709 | 37,373,437 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $203.46 |
52-Week Low | $33.16 | $22.36 |
Typical Hold Time | 72 Days | 59 Days |
Enterprise Value | $83.81B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.65, up 1.8% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $0.30 exceeding expectations. Revenue growth accelerated to $8.29B in 2025 with impressive 23.08% net margins. Analyst consensus is bullish with 52% buy ratings and $98.22 price target, representing 125% upside potential. Recent 1:2 stock split on August 11, 2026, enhances accessibility while maintaining zero long-term debt.
MNST presents compelling growth prospects with international expansion driving 35% sales surge and clean balance sheet. However, elevated valuation multiples (P/E 40.42) and regulatory challenges in key markets like India pose risks. The stock's technical strength and fundamental momentum support continued upside, though investors should monitor margin pressures from inflation and competitive dynamics in the energy drink sector.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
